Exchange: NASDAQ·Updated 07:59 PM EDT

AMGN News

News
all
press releases
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.
Stocktwits
More News
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
Zacks
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Sept. 2, 2026 THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 2026Wells Fargo Healthcare...
PR Newswire
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.
Zacks
Aging Population Drives Healthcare Growth: Stocks to Watch
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.
Zacks
Stock Futures Drop To Close Out August As Oil Jumps On Renewed Iran Hostilities
Stock Futures Drop To Close Out August As Oil Jumps On Renewed Iran Hostilities US stock futures dropped in thin trading with most traders out as summer draws to a close, while oil prices jumped after the US and Iran exchanged attacks for first time in weeks. Brent futures rallied...
Zero Hedge
AMGEN'S REPATHA REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
AMGEN'S REPATHA REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE AMGEN'S REPATHA REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE PR Newswire THOUSAND OAKS, Calif., Aug. 31, 2026 Repatha is the First and Only PCSK9 Inhibitor Shown to...
PR Newswire
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAmgen is a diversified pharmaceutical giant with high net margins. It reported nearly $8.1 billion in free cash flow for fiscal 2025...
Nasdaq News: Markets
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.
Zacks

Advertisement|Remove ads.